For COVID-19 vaccine updates, please review our information guide and sign up for Connect. Continue your routine care with us by scheduling an in-person appointment or Video Visit.

Warning message

The subscription service is currently unavailable. Please try again later.


Optimizing Treatment With Ibrutinib in High-Risk CLL

Saturday, February 7, 2015

Richard Furman, M.D., director of Weill's CLL Research Center, participates in a panel discussion via OncLive about therapy for patients with chronic lymphocytic leukemia (CLL) whose tumors harbor a 17p deletion (a group that only represents about 5 percent to 10 percent of patients at the time of initial treatment) with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib.